Clinical trial NCT06868043: A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Official title: A Study to Investigate the Function, Safety and Tolerability of a Transdermal Continuous Glucose Monitoring System in Diabetic Patients (Type 1 and 2) for a Period of 28 Days
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Diabetes (DM)
Keywords: diabetes management
continuous glucose monitoring
Lead sponsor: EyeSense GmbH
Sponsor class: INDUSTRY
First posted: 2025-03-10
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2). Duration up to 11 weeks: up to 6 weeks of screening phase (42 days); 4 weeks of treatment/measurement phase (28 days, depending on sensor functionality) and 1 week of follow up (7 days)

Detailed description: This study is an investigational study, which will be conducted only at one site in Germany. The investigators, the patient and the sponsor will be unblinded.

The eligibility of the patient is determined in up to two steps, a screening (see inclusion criteria) and in case of women of childbearing potential a urine pregnancy test at the day of sensor insertion (independent of any re-screening). Women of childbearing potential are only enrolled after a negative outcome of the urine pregnancy test. The screening results are valid up to 42 days. Within that time the first measurement visit including the insertion of the device should be performed. If the first measurement visit is delayed a re-screening has to be performed. Should the patient not pass the re-screening, the patient is considered as a screening failure and must be excluded.

The trial is structured into three phases, the screening/enrolment phase, the insertion/measurement phase and the follow-up phase.

Screening/Enrolment Phase: Up to 6 weeks (42 days), 1 visit

Insertion/Measurement phase: Up to 4 weeks (28 days), up to 6 in-house measurement visits

Follow-up Phase: 1 week (7 days), 1 visit

Eligibility criteria: Inclusion Criteria:

* Body mass index within the range of 19-40 kg/m2, inclusive
* Diabetes type 1 and 2
* Females (if of childbearing potential) must agree to abstain from sexual intercourse or use reliable forms of contraception e.g. condom or diaphragm with spermicide or oral contraceptives to prevent pregnancy during the study
* Negative urine pregnancy test immediately before sensor insertion (only women of childbearing potential)
* Signed written Informed Consent

Exclusion Criteria:

* Inability to follow the protocol schedule
* Participating in another clinical trial
* Pregnant or lactating females, , including positive urine pregnancy test immediately before sensor insertion
* Any known hypersensitivity to any of the products used in the study, including preservatives etc. Especially hypersensitivity against legumes
* Tattoos at the abdominal or upper arm skin area where the fiber sensor is supposed to be placed
* Malignancies requiring therapy during the study
* Severe chronic diseases e.g. renal failure, liver cirrhosis etc. which may interfere with the conduct or completion of the study
* Acute severe infection disease at the time of enrolment
* Alcohol and/or drug addiction
* Vulnerable patients (e.g. persons kept in detention)
* Poorly controlled diabetes mellitus with hemoglobin A1C higher than 10%

Primary outcomes:
measure: Short and mid term performance of the transdermal CGM sensor determined as MARD
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: Incidence of adverse events
timeFrame: 0, 3, 7,14, 21, 28 and 35-38 days
Secondary outcomes:
measure: Stability of the blood glucose to fluorescence correlation
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: Changes in blood glucose to fluorescence lag time over a period of up to 28 days
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: Correlation between the fluorescence readings of the sensor and capillary blood glucose measurements
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: Signal-to-noise ratio
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: Signal drift
timeFrame: 0, 3, 7, 14, 21 and 28 days
measure: User satisfaction assessed by the Likert scale
timeFrame: 35-38 days
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Diabetes Instiut Heidelberg
Study officials:
affiliation: Diabetesinstitut Heidelberg
name: Christoph Hasslacher, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: